Sponsored By:

7 Biotech Stocks to Buy

An aging population can be a good play for your portfolio

   

chemical stocks 185 7 Biotech Stocks to BuyBiotech and healthcare stocks are great investments for the long term. After all, the one thing we can be certain of in life is the health troubles that come with aging. Helping people lead longer, more productive lives is not just an important service but it’s also a profitable industry for the top stocks in the field.

I watch more than 5,000 publicly traded companies with my Portfolio Grader tool, ranking companies by a number of fundamental and quantitative measures. And this week, seven biotech stocks look ready to buy.

Here they are, in alphabetical order. Each one of these stocks gets an “A” or “B” according to my research, meaning it is a “strong buy” or “buy.”

Alexion (NASDAQ:ALXN) is a biotech company that serves patients with severe and ultra-rare disorders. In the last year, ALXN stock has gained 84%, compared to a 5% gain for the Dow Jones in the same time. Alexion stock gets an “A” grade for sales growth, a “B” grade for operating margin growth, an “A” grade for earnings growth, a “B” grade for earnings momentum, a “B” grade for its ability to exceed the consensus earnings estimate on Wall Street, an “A” grade for the magnitude in which earnings projections have increased over the past months, and a “B” grade for return on equity. For more information, view my complete analysis of ALXN stock.

Amgen (NASDAQ:AMGN) discovers, develops, manufactures and markets medicines for grievous illnesses. In the last 12 months, Amegen stock has gained 26%. AMGN stock gets a “B” grade for the magnitude in which earnings projections have increased over the past months, a “B” grade for cash flow, and an “A” grade for return on equity. For more information, view my complete analysis of AMGN stock.

Biogen (NASDAQ:BIIB) works with neuro-degenerative diseases, hemophilia and autoimmune disorders. Biogen stock is up 75% since last April. BIIB stock gets a “B” grade for operating margin growth, a “B” grade for earnings growth, a “B” grade for cash flow, and an “A” grade for return on equity. For more information, view my complete analysis of BIIB stock.

Celgene (NASDAQ:CELG) treats cancer and immune-inflammatory related diseases and has experienced 40% stock growth in the last year. Celgene stock gets a “B” grade for sales growth, a “B” grade for operating margin growth, an “A” grade for earnings growth, a “B” grade for earnings momentum, an “A” grade for the magnitude in which earnings projections have increased over the past months, a “B” grade for cash flow, and an “A” grade for return on equity. For more information, view my complete analysis of CELG stock.

Gilead Sciences (NASDAQ:GILD) is a research-based biopharmaceutical company that has watched its stock value increase 15% in the last three months. Gilead stock gets a “B” grade for earnings momentum, an “A” grade for cash flow, and an “A” grade for return on equity. For more information, view my complete analysis of GILD stock.

Regeneron (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. In the last 12 months, Regeneron stock has jumped 167%. Regeneron stock gets an “A” grade for the magnitude in which earnings projections have increased over the past months. For more information, view my complete analysis of REGN stock.

Vertex (NASDAQ:VRTX) deals with small molecule drugs and is up 22% since the start of 2012. Vertex stock gets an “A” grade for sales growth, an “A” grade for earnings momentum, and a “B” grade for return on equity. For more information, view my complete analysis of VRTX stock.

 Get more analysis of these picks and other publicly-traded stocks with Louis Navellier’s Portfolio Grader tool, a 100% free stock-rating tool that measures both quantitative buying pressure and eight fundamental factors.

 


Article printed from InvestorPlace Media, http://investorplace.com/2012/04/7-biotech-stocks-to-buy-amgn-biib-celg-gild-regn/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.